NEW YORK (TheStreet) --Shares of Eli Lilly (LLY) were lower in mid-afternoon trading on Tuesday after a tweet by U.S. Senator Bernie Sanders (I-VT) questioned the price of Eli Lilly's diabetes treatment Humalog.
"Why has the price of Humalog insulin gone up 700% in 20 years? It's simple. The drug industry's greed," Sanders said on Twitter (TWTR).
TIAA Global Asset Management managing director Stephanie Link owns Eli Lilly shares, and responded to the stock's decline today during CNBC's "Fast Money Halftime Report."
"It's a great company, it's got a great pipeline, an outstanding management team and it's got a great balance sheet," she said. "It's absolutely one of the blue chips in this sector."
Humalog, is "not a big percentage of their total revenue," she noted.
Humalog represents about 12% of Eli Lilly's total revenue, according to the company's most recent quarterly release.
Link nonetheless urged caution when buying a stock in the healthcare space.
"You have to be careful. At some point, you buy it on yield because that balance sheet is very strong, but I'm not rushing to get in the way of all this headline risk," she said.
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author. TheStreet Ratings has this to say about the recommendation:
We rate LILLY (ELI) & CO as a Buy with a ratings score of B+. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.